{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/renal-or-ureteric-colic-acute/background-information/causes/","result":{"pageContext":{"chapter":{"id":"752239d5-81f6-57cf-a145-75fe4fc4be12","slug":"causes","fullItemName":"Causes","depth":2,"htmlHeader":"<!-- begin field c0bd5e10-1f97-4135-9e3f-f47016c39c45 --><h2>What causes it?</h2><!-- end field c0bd5e10-1f97-4135-9e3f-f47016c39c45 -->","summary":"","htmlStringContent":"<!-- begin item fa907f4f-a729-483b-a11d-55e3465c79c4 --><!-- begin field 0e1c3ed7-70c6-4338-9c0d-1cd9f9f4e204 --><ul><li><strong>Renal or ureteric colic is usually caused by a urinary stone.</strong><strong> </strong><ul><li>Urinary stones are often asymptomatic but may cause pain when they move or obstruct the flow of urine through the ureter [<a class=\"bibliography-reference internal-reference\" href=\"/topics/renal-or-ureteric-colic-acute/references/\">PHE and IIAC</a>].</li><li>Obstruction of urinary flow causes an increase in tension in the urinary tract wall. The increasing pressure stimulates the synthesis and release of prostaglandins, and subsequent vasodilatation induces a diuresis which further increases pressure within the kidney [<a class=\"bibliography-reference internal-reference\" href=\"/topics/renal-or-ureteric-colic-acute/references/\">Masarani and Dinneen, 2007</a>].</li><li>Pain from urinary stones can also be due to smooth muscle spasm (as a result of prostaglandins acting directly on the ureter), hyperperistalsis (due to the obstruction), oedema, and mucosal irritation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/renal-or-ureteric-colic-acute/references/\">Masarani and Dinneen, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/renal-or-ureteric-colic-acute/references/\">BPAC NZ, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/renal-or-ureteric-colic-acute/references/\">BMJ, 2018</a>].</li><li>Urinary stones usually obstruct at one of three sites: the vesico-ureteric junction, in the mid-ureter where the ureter crosses the iliac vessels, or the pelvi-ureteric junction [<a class=\"bibliography-reference internal-reference\" href=\"/topics/renal-or-ureteric-colic-acute/references/\">Stewart and Joyce, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/renal-or-ureteric-colic-acute/references/\">Eisner et al, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/renal-or-ureteric-colic-acute/references/\">Bultitude and Rees, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/renal-or-ureteric-colic-acute/references/\">Patti, 2019</a>].</li></ul></li><li><strong>Urinary stones form when the urine becomes excessively supersaturated with a mineral, leading to crystal formation. </strong>Once crystals are formed, they either pass out with the urine or are retained in the kidney, where they can grow and form stones [<a class=\"bibliography-reference internal-reference\" href=\"/topics/renal-or-ureteric-colic-acute/references/\">Khan, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/renal-or-ureteric-colic-acute/references/\">BMJ, 2018</a>].<ul><li>Calcium stones make up about 80% of urinary stones and my be calcium oxalate stones (80% of cases) or calcium phosphate stones (20% of cases) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/renal-or-ureteric-colic-acute/references/\">Khan, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/renal-or-ureteric-colic-acute/references/\">BMJ, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/renal-or-ureteric-colic-acute/references/\">EAU, 2018</a>].<ul><li>Calcium oxalate stones are associated with low urine volume, hypercalciuria, hyperuricosuria, hyperoxaluria, and hypocitraturia.</li><li>Calcium phosphate stones (hydroxy apatite or brushite) are associated with low urine volume, hypercalciuria, hypocitraturia, high urine pH, and conditions such as primary hyperparathyroidism and renal tubular acidosis.</li></ul></li><li>Uric acid stones make up about 10–20% of urinary stones and are associated with hyperuricosuria and a low urinary pH (less than 5.5).</li><li>Struvite stones (also known as infection stones) make up 1–5% of urinary stones and result from bacterial infection that hydrolyzes urea to ammonium and raises urine pH (greater than 7.2) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/renal-or-ureteric-colic-acute/references/\">Morgan, 2016</a>]. They consist of a mixture of magnesium, ammonium, and phosphate.</li><li>Cystine stones make up 1% of urinary stones and result from cystinuria, a genetic disorder that causes cystine to leak through the kidneys and into the urine.</li><li>Drug-induced stones represent about 1% of all urinary stones [<a class=\"bibliography-reference internal-reference\" href=\"/topics/renal-or-ureteric-colic-acute/references/\">Alelign, 2019</a>]. They are formed by crystallized compounds of a drug or due to unfavourable changes in urine composition during drug treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/renal-or-ureteric-colic-acute/references/\">EAU, 2018</a>].<ul><li>Drugs that impair urine composition include acetazolamide, allopurinol, aluminium magnesium hydroxide, ascorbic acid, calcium, furosemide, laxatives, vitamin D, and topiramate.</li><li>Drugs that cystallize in urine include allopurinol/oxypurinol, amoxicillin/ampicillin, ceftriaxone, quinolones, ephedrine, indinavir, magnesium trisilicate, sulphonamides, triamterene, and zonisamide.</li></ul></li></ul></li></ul><!-- end field 0e1c3ed7-70c6-4338-9c0d-1cd9f9f4e204 --><!-- end item fa907f4f-a729-483b-a11d-55e3465c79c4 -->","topic":{"id":"cdafd21d-4810-57d3-8f62-82a1a19fdfca","topicId":"a218f6a4-ed45-4224-aff1-78febfb7ee5e","topicName":"Renal or ureteric colic - acute","slug":"renal-or-ureteric-colic-acute","lastRevised":"Last revised in August 2020","chapters":[{"id":"7b6dbc7b-1f23-5ee3-961a-d0bb132e79a9","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"1ec2c876-583e-52dd-acd5-47c4caa558f6","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"c7ce9e2f-a6ff-5bab-8c4d-cf4a22ce5aee","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d7d22a9e-02ff-5e8b-862f-f898250c4678","slug":"changes","fullItemName":"Changes"},{"id":"98fe1c4c-3205-5b7f-bbed-cd17ded43d45","slug":"update","fullItemName":"Update"}]},{"id":"509a1ed2-ed44-5581-8f49-eb749b9ea020","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"0e821f32-03d6-517d-8499-ebdcea3b1678","slug":"goals","fullItemName":"Goals"},{"id":"df7713ac-8d59-50fe-a123-0d242c30e093","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"853aca77-2834-5f1d-a3e4-01aeebb729d4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"1f120db3-685a-599e-bc97-42cd544ce6e3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"54a60174-eb3f-574f-bb93-5b6f8b5e8d06","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8bd006d1-b12b-5d0e-be62-b923a31bd0cd","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"65585660-f42f-5565-b5d0-02016f948e73","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"652198ec-7ef4-5687-9238-d38453ab5cd4","slug":"definition","fullItemName":"Definition"},{"id":"752239d5-81f6-57cf-a145-75fe4fc4be12","slug":"causes","fullItemName":"Causes"},{"id":"2d4d0d05-f0fd-543d-9e5f-8713a51bfc66","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"79145281-9da8-535a-83c8-cbb4a72e9d11","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ef59df09-2026-56ef-8cbb-afb1e4847ab2","slug":"prognosis","fullItemName":"Prognosis"},{"id":"94a264f3-c14c-59ca-8c33-bd24f87514ac","slug":"complications","fullItemName":"Complications"}]},{"id":"6d79c4a3-97a3-5f80-bc33-947d733fddf3","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"24db2d43-f317-56b6-996e-0f575cffd101","slug":"assessment","fullItemName":"Assessment"},{"id":"f638a0b0-3a69-566b-a73d-7d56cff2f3b9","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"dc820ada-52a1-56fd-9c66-60a28376c542","fullItemName":"Management","slug":"management","subChapters":[{"id":"629113ef-a0be-50de-aa70-659a4b59e590","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"ebf234d9-646e-552f-b466-aaca66236f57","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"298f2308-05a8-593c-8bb7-a5f86eac5de4","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"b6ff1814-0e3c-5cc7-8275-ff74fdceae11","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"d7ba1f73-3320-55f7-983c-b22a1bdf9f6a","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"21bf69fe-a252-5365-a0da-d9d8d09d7512","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"19b93905-b022-57b7-a88e-c227f3e2a11a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1a3d0872-5a81-5ea8-86ec-64dab9d2054f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"b4d5af0f-a934-5a43-8130-e3047335079c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"65585660-f42f-5565-b5d0-02016f948e73","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}